<DOC>
	<DOCNO>NCT00777920</DOCNO>
	<brief_summary>This Phase 3 , international , multicenter , open-label study monitor long-term safety ambrisentan adult pulmonary hypertension . The available ambrisentan dos study 5 10 mg administer orally daily ; approve dos ambrisentan United States , Canada , European Union 5 10 mg. Investigators able adjust ambrisentan dose clinically indicate . A minimum 4 week dose adjustment require . Participants receive therapy pulmonary hypertension contraindicate concomitant use ambrisentan permit enroll study continue receive therapy . Participants enrol study receive treatment ambrisentan time investigator participant choose stop ambrisentan treatment , ambrisentan becomes commercially available , Sponsor stop study .</brief_summary>
	<brief_title>Study Ambrisentan Subjects With Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Men woman pulmonary hypertension ( PH ) discontinue clinical study ambrisentan due study closure Sponsor . Eligible subject participate country ambrisentan yet commercially available . Subjects participate country ambrisentan commercially available may eligible qualify treatment per current prescribe information country . Subjects discontinue ambrisentan clinical study reason Sponsorinitiated study closure eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>